Literature DB >> 23246970

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.

J R Todd1, L L Scurr1, T M Becker1, R F Kefford2, H Rizos1.   

Abstract

Stimulation of the c-Kit receptor tyrosine kinase has a critical role in the development and migration of melanocytes, and oncogenic c-Kit mutants contribute to the progression of some melanomas. c-Kit signalling activates the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways and their relative contribution to the activities of oncogenic and ligand-dependent c-Kit remains uncertain. We show that PI3K is a major regulator of MAPK activation in response to c-Kit activity and the dominant effector of c-Kit-driven melanocyte proliferation and melanoma survival. Nevertheless, inhibition of the PI3K pathway in c-Kit mutant melanoma cells did not replicate the apoptotic efficacy of the c-Kit inhibitor, imatinib mesylate. Instead, the simultaneous suppression of the PI3K and MAPK pathways promoted a strong synergistic apoptotic effect. These data indicate that MAPK functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Thus, the concurrent inhibition of PI3K and MAPK signalling is required to suppress oncogenic c-Kit activity and may provide an effective therapeutic strategy in c-Kit mutant melanomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23246970     DOI: 10.1038/onc.2012.562

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.

Authors:  J Cho; S Y Kim; Y J Kim; M H Sim; S T Kim; N K D Kim; K Kim; W Park; J H Kim; K-T Jang; J Lee
Journal:  Clin Transl Oncol       Date:  2017-04-18       Impact factor: 3.405

Review 2.  Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma.

Authors:  Philip Eliades; Keith T Flaherty; Hensin Tsao
Journal:  Melanoma Manag       Date:  2015-05-18

3.  Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma.

Authors:  Junna Oba; Sun-Hee Kim; Wei-Lien Wang; Mariana P Macedo; Fernando Carapeto; Meredith A McKean; John Van Arnam; Agda K Eterovic; Shiraj Sen; Charuta R Kale; Xiaoxing Yu; Cara L Haymaker; Mark Routbort; Lauren E Haydu; Chantale Bernatchez; Alexander J Lazar; Elizabeth A Grimm; David S Hong; Scott E Woodman
Journal:  JCO Precis Oncol       Date:  2018-06-05

4.  Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.

Authors:  F Laugier; J Delyon; J André; A Bensussan; N Dumaz
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

5.  KIT Suppresses BRAFV600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling.

Authors:  James V Neiswender; Robert L Kortum; Caitlin Bourque; Melissa Kasheta; Leonard I Zon; Deborah K Morrison; Craig J Ceol
Journal:  Cancer Res       Date:  2017-09-25       Impact factor: 12.701

Review 6.  Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.

Authors:  Ross L Pearlman; Mary Katherine Montes de Oca; Harish Chandra Pal; Farrukh Afaq
Journal:  Cancer Lett       Date:  2017-01-25       Impact factor: 8.679

7.  MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

Authors:  Yao Zhan; Jun Guo; William Yang; Christophe Goncalves; Tomasz Rzymski; Agnieszka Dreas; Eliza Żyłkiewicz; Maciej Mikulski; Krzysztof Brzózka; Aniela Golas; Yan Kong; Meng Ma; Fan Huang; Bonnie Huor; Qianyu Guo; Sabrina Daniela da Silva; Jose Torres; Yutian Cai; Ivan Topisirovic; Jie Su; Krikor Bijian; Moulay A Alaoui-Jamali; Sidong Huang; Fabrice Journe; Ghanem E Ghanem; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2017-10-16       Impact factor: 14.808

8.  Resistance to c-Kit inhibitors in melanoma: insights for future therapies.

Authors:  Matteo S Carlino; Jason R Todd; Helen Rizos
Journal:  Oncoscience       Date:  2014-06-06

9.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Authors:  F Stephen Hodi; Christopher L Corless; Anita Giobbie-Hurder; Jonathan A Fletcher; Meijun Zhu; Adrian Marino-Enriquez; Philip Friedlander; Rene Gonzalez; Jeffrey S Weber; Thomas F Gajewski; Steven J O'Day; Kevin B Kim; Donald Lawrence; Keith T Flaherty; Jason J Luke; Frances A Collichio; Marc S Ernstoff; Michael C Heinrich; Carol Beadling; Katherine A Zukotynski; Jeffrey T Yap; Annick D Van den Abbeele; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

Review 10.  Revisiting determinants of prognosis in cutaneous melanoma.

Authors:  Sarah A Weiss; Douglas Hanniford; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.